1 minute read

Our Next Generation Sequencing panels for solid tumours and haematological malignancies

Our NGS panels have been designed by oncologists for oncologists to cover the most common cancer related genes in solid tumour and haematological malignancies, required for determining treatment pathways:

Full NGS Panel

Core NGS Panel

Bespoke DNA NGS Panel

RNA Pan-Cancer NGS Panel

Single Gene Targeted NGS

Targeted NGS CRC Screen

Full gene sequences for 200 of the most common cancer related genes and chromosome level copy number variation (CNV)

Hotspot/full gene sequences for most common cancer related genes: the essential genes required for determining treatment pathways

Choose from our 200+ gene panel, the most relevant cancer genes, to help determine treatment pathways

Targets 1385 cancer genes for gene expression, variant, and fusion detection with known and novel gene fusion partners, allowing a comprehensive view of cancer pathways. In particular this methodology is used to identify NTRK fusion-positive solid tumours in adults and children to direct the use of Larotrectinib, as per NICE guidance

Hotspot/full gene sequence for a single cancer related gene required for determining treatment pathways

Hotspot/full gene sequence for a CRC related gene (KRAS, NRAS, BRAF) required for determining treatment pathways

Additional Gene Reporting Analysis and reporting of additional cancer related genes from the NGS panel required for determining treatment pathways

Circulating tumour DNA (ctDNA) testing is the process of taking a sample of body fluid (liquid biopsy) and testing it for the presence of tumour DNA, which is shed by tumour cells into the circulation. The Marsden360 assay is used for tumour mutation profiling from a liquid biopsy, for patients with any solid malignant neoplasm. Using highly sensitive Next Generation DNA sequencing (NGS), multiple abberations across multiple genes (74 gene panel, including fusions) can be detected with improved test sensitivity and specificity, resulting in improved clinical outcomes

This article is from: